Yu-Qin Sun, Qing Zhong, Chen-Bin Lv, Ji-Yun Zhu, Guang-Tan Lin, Zhi-Quan Zhang, Dong Wu, Cai-Ming Weng, Qiu-Xian Chen, Ming-Qiao Lian, Wei-Ming Zeng, Yong-Bin Zhang, Qi-Yue Chen, Jian-Xian Lin, Jian-Wei Xie, Ping Li, Chao-Hui Zheng, Jun Lu, Li-Sheng Cai, Chang-Ming Huang
BACKGROUND: The safety and efficacy of neoadjuvant immunochemotherapy (nICT) for locally advanced gastric cancer (LAGC) remain controversial. METHODS: Patients with LAGC who received either nICT or neoadjuvant chemotherapy (nCT) at 3 tertiary referral teaching hospitals in China between January 2016 and October 2022 were analysed. After propensity-score matching (PSM), comparing the radiological response, pathological response rate, perioperative outcomes, and early recurrence between the two groups...
April 23, 2024: International Journal of Surgery